about
Vaccine against Helicobacter pylori: Inevitable approachTherapy of Helicobacter pylori: present medley and future prospectiveHelicobacter pylori: Emergence of a SuperbugHelicobacter pylori: A Beneficial Gastric Pathogen?Role of dupA in virulence of Helicobacter pyloriHelicobacter pylori homB, but not cagA, is associated with gastric cancer in IranComment on "Gastric and colon metastasis from breast cancer: case report, review of the literature, and possible underlying mechanisms".Novel Idea: Virulence-Based Therapy Against Helicobacter pylori Infection (Smart Therapy).The Helicobacter pylori dupA: A Novel Biomarker for Digestive Diseases.Comment on "Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients".Helicobacter pylori treatment: New perspectives using current experience.Comment on "Helicobacter pylori Outer Membrane Protein 18 (Hp1125) Is Involved in Persistent Colonization by Evading Interferon- γ Signaling".Vaccine as absolute solution of Helicobacter pylori infection.Comment on "Lack of Association Found between Helicobacter pylori Infection and Diarrhea-Predominant Irritable Bowel Syndrome: A Multicenter Retrospective Study".Recombination and phenotype evolution dynamic of Helicobacter pylori in colonized hosts.Comment on "Bacteria in Cancer Therapy: Renaissance of an Old Concept".Binding of the Helicobacter pylori OipA causes apoptosis of host cells via modulation of Bax/Bcl-2 levels.Comment on "Characteristics and Risk Factors of Helicobacter pylori Associated Gastritis: A Prospective Cross-Sectional Study in Northeast Thailand".First case of Helicobacter pylori infection resistant to seven antibiotics in Iran.Considerable use of furazolidone in Iran.Call for global vaccine instead of Helicobacter pylori blind antibiotic therapy.Updated Helicobacter pylori management in 2015.Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran.Low frequency of cagA-positive Helicobacter pylori strains isolated from Iranian patients with MALT lymphoma.Letter: more studies are needed to elucidate any association between Helicobacter pylori infection and Barrett's metaplasia.Obesity and Helicobacter pylori: An undefined association.Different Look in to the Role of Flagella in Pathogenesis of Helicobacter pylori.In vivo and in vitro experiments before new direction on clinical management of any diseases attributed with Helicobacter pylori.Optimised Helicobacter pylori antibiotic susceptibility profile using gold-standard method.Reliability of rapid urease test for screening gastric cancer in high-risk populations.High correlation of babA 2-positive strains of Helicobacter pylori with the presence of gastric cancer.Helicobacter pylori therapy and clinical perspective.Comment on "First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin".Prevalence of horB gene among the Helicobacter pylori strains isolated from dyspeptic patients: first report from Iran.Not an easy road to generate an effective Helicobacter pylori vaccine.Helicobacter pylori and Gastric Cancer.Diagnosis of Helicobacter pylori Using Invasive and Noninvasive Approaches.Future of Helicobacter pylori and its feasibilityPrimary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in IranLetter: inverse correlation between Helicobacter pylori and obesity - a conclusion too early?
P50
Q26752743-232BBF78-6FEC-4C64-BF11-F5FDFDFBD21CQ26823120-AE0DC770-0B4C-417B-8522-77820F135267Q27001579-BEB02FDF-3896-4BD1-9294-767BE7A7F034Q27021020-3880758E-0795-452C-9719-B920C6A04629Q28076864-31436ED4-BB30-4C9E-94E0-EC2A09BA5685Q35192226-B7622879-60DB-4105-98B8-E71C2C50B897Q37684626-CBF214D8-D026-4229-8E40-4D424CE81301Q38364233-FC640E26-2B30-443D-B8D7-5F3A5828130FQ38376455-63D3F2EC-0433-4E74-85CA-5D1E10CFE6B2Q38527480-25073986-DA83-483B-B3F0-61E491850025Q39107923-23F56071-0311-4F1F-ADCA-486959CD8623Q39770220-1697AD51-E64E-451F-9341-E0595F4C5BC5Q40295488-0E276532-B8A9-4DAA-AA11-83C811A9ED53Q40468314-06CD3FD2-D33C-4369-B8E2-B840F563857AQ40712902-57E18D6D-D490-4D29-A454-8D8FABE5EDEEQ41200725-EBFECC12-4F4A-4E3F-8ADC-19387B06D884Q41388633-A5A3EEA7-7B80-4429-8DCE-148ED8FB3644Q41433589-187092B3-D50E-4541-A9A4-EC275215FDFEQ41622932-35B4DEDF-91C1-416E-B815-B92069460E70Q42338475-5740FED3-D075-4169-8CC7-23E8796F53C5Q42359458-9FB2A548-65F0-4CE1-B596-5E6CEFEDB56FQ42585485-59C5F81B-C664-4206-9659-B45E9C8008CEQ42819327-DD18070F-8746-4568-A9F0-B859E5B36A91Q43636367-9D424C52-0D04-46CD-A970-EAA991779B22Q44643287-8CD5EFAA-1EFB-41F8-B7A1-26B5C8A3767EQ48186256-3686B7FB-1DF8-43C4-8F03-343A3F51A61FQ48218217-3486AEBF-DAF6-4D7B-AFE7-90717A150D30Q48258580-50ADED63-9DAC-4548-B71A-8901964D84F5Q49642187-E7F20C3E-F4FC-49CE-8C91-20E940F2E483Q49991237-C892A8AC-3305-4C2F-A525-9BAC836852DAQ51460095-2E551C54-5D6E-48A9-9952-84EFE5AABF3DQ52341166-B4631068-2B0C-4EA5-8891-D1060051BF36Q52575016-896FA14B-883F-4AD4-B555-F94ADBB4060EQ54373752-3196E6C9-4E09-4C61-9CA5-B07C6CA734C2Q54420361-6CE211F3-3CBE-4C74-BD04-94A58878344AQ54989296-3E1D0689-5247-4966-BFBF-06137AEFADA9Q55301374-F3D20D8C-41C8-42AC-A96D-CEB238F0CDF3Q57157542-9C8CB08D-AC1C-4F08-8109-E3F969244C8EQ83709895-F1E3BA6E-0051-4CF1-8800-AE42E60117B4Q85674155-06B02BB1-D1CC-4F3C-BDD5-B75713128C0D
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Amin Talebi Bezmin Abadi
@ast
Amin Talebi Bezmin Abadi
@en
Amin Talebi Bezmin Abadi
@es
type
label
Amin Talebi Bezmin Abadi
@ast
Amin Talebi Bezmin Abadi
@en
Amin Talebi Bezmin Abadi
@es
prefLabel
Amin Talebi Bezmin Abadi
@ast
Amin Talebi Bezmin Abadi
@en
Amin Talebi Bezmin Abadi
@es
P1053
L-5487-2017
P106
P1153
36611308600
P21
P2798
P31
P3829
P496
0000-0001-5209-6436